Reporting of remaining stocks for the wholesalers
Disruptions or shortages in the supply of medicines, both in Latvia and in Europe, have become more frequent in recent years, for various reasons, such as production difficulties or problems with the quality of medicines, and such disruptions can leave a significant impact on public health. Pharmaceutical industry is under supervision from the authorities, and they are trying to reduce disruptions in the supply of medicines in multiple ways. One of the ways to reduce the potential harms of drug shortages is to plan ahead and identify the needs for internal market, in order to make it more efficient, changes have been introduced in Cabinet Regulation No. 416 “Procedures Regarding the Distribution and Quality Control of Medicinal Products”. Changes suggest submitting a report every workday until 10:00 a.m. to the State Agency of Medicines on the number of remaining packages in stock for the specific day. The information is publicly available in the Latvian Register of Medicines.
To comply with the changes BRIZ, as a pharmaceutical wholesaler, has developed internal procedures for reporting the remaining stock. BRIZ welcomes these changes with positivity, as transparent information on real collateral for the domestic market is publicly available. The primary beneficiary is the consumer, as information on reference medicines and analogue medicines is available to the public. The reporting makes it possible to plan the procurement of medicines more effectively, with the goal of reducing drug supply disruptions and reducing the possibility of artificial shortages.